AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23214255 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine + CXC
Number of subjects: 46
Study 20480414 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative stereotype activation
Number of subjects: 117
Study 20480414 — intervention group
Group type: COMPARATOR
Intervention: Positive or neutral stereotype activation
Number of subjects: 117
Study 16859864 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling intervention (1.5 hours of counseling plus telephone follow-up by a masters prepared mental health counselor)
Number of subjects: 105
Study 16859864 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard cessation advice from the health care provider)
Number of subjects: 105
Study 15851220 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized AV delay determined by Doppler echocardiography (group 1, n = 20)
Number of subjects: 40
Study 15851220 — intervention group
Group type: COMPARATOR
Intervention: Empiric AV delay of 120 ms (group 2, n = 20)
Number of subjects: 40
Study 11094650 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 0
Study 11094650 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hormone replacement therapy (HRT)
Number of subjects: 0
Study 11094650 — intervention group
Group type: COMPARATOR
Intervention: Observational studies of ERT
Number of subjects: 0
Study 9156960 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 10
Study 8438612 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral administration of a killed typhoid vaccine
Number of subjects: 17
Study 8438612 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral vaccination
Number of subjects: 17
Study 8438612 — intervention group
Group type: COMPARATOR
Intervention: Oral vaccination
Number of subjects: 17
Study 3514550 — intervention group
Group type: EXPERIMENTAL
Intervention: relaxation with EMG and thermal biofeedback
Number of subjects: 16
Study 3514550 — intervention group
Group type: COMPARATOR
Intervention: person‐centered insight therapy
Number of subjects: 16
Study 30308524 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope laryngoscope
Number of subjects: 44
Study 30308524 — intervention group
Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope
Number of subjects: 44
Study 28587621 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, structured intervention (self-help booklet + one proactive call)
Number of subjects: 300
Study 28587621 — intervention group
Group type: COMPARATOR
Intervention: Usual care (motivational interviewing with tailored proactive and reactive calls)
Number of subjects: 300
Study 25941016 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP-825 (22 mg sumatriptan powder)
Number of subjects: 275
Study 25941016 — intervention group
Group type: COMPARATOR
Intervention: 100 mg oral sumatriptan
Number of subjects: 275
Study 23712687 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical noise applied to ankle muscle tendons at mean amplitudes of 20, 30, 100, and 280 μm
Number of subjects: 0
Study 23712687 — intervention group
Group type: COMPARATOR
Intervention: Microneurography without noise application
Number of subjects: 0
Study 23712687 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneurography with optimal level of noise application
Number of subjects: 0
Study 23712687 — intervention group
Group type: COMPARATOR
Intervention: Cutaneous afferents with and without noise application
Number of subjects: 0
Study 21431391 — intervention group
Group type: EXPERIMENTAL
Intervention: S-POP system
Number of subjects: 511
Study 20559976 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) peri-infarct pacing delivered via biventricular pacemakers
Number of subjects: 110
Study 20559976 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 110
Study 17893569 — intervention group
Group type: EXPERIMENTAL
Intervention: Low proportions of CD3+CD4+CD69+ cells before treatment
Number of subjects: 31
Study 17893569 — intervention group
Group type: EXPERIMENTAL
Intervention: Low proportions of CD3+CD56+ cells before treatment
Number of subjects: 31
Study 17893569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment proportion of CD3+CD4+CD69+ cells
Number of subjects: 31
Study 17893569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment proportion of CD3+CD56+ cells
Number of subjects: 31
Study 16371039 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT apheresis PLTs
Number of subjects: 645
Study 11952312 — intervention group
Group type: EXPERIMENTAL
Intervention: CTF-guided puncture (group A)
Number of subjects: 75
Study 11952312 — intervention group
Group type: COMPARATOR
Intervention: Sequential CT-guided puncture (group B)
Number of subjects: 75
Study 9607383 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg losartan
Number of subjects: 567
Study 9607383 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg irbesartan
Number of subjects: 567
Study 9607383 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg irbesartan
Number of subjects: 567
Study 9607383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 567
Study 8582490 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliveries directed by obstetricians
Number of subjects: 1034
Study 8582490 — intervention group
Group type: EXPERIMENTAL
Intervention: Primiparous deliveries
Number of subjects: 1034
Study 8582490 — intervention group
Group type: COMPARATOR
Intervention: Midwives and general practitioners
Number of subjects: 1034
Study 1700218 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 443C81 (0.46 +/- 0.11 microgram/ml)
Number of subjects: 6
Study 1700218 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose 443C81 (1.0 +/- 0.2 microgram/ml)
Number of subjects: 6
Study 1700218 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study 1700218 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of 443C81
Number of subjects: 6
Study 359266 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water by sip
Number of subjects: 15
Study 359266 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot chicken soup by sip
Number of subjects: 15
Study 359266 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot chicken soup by straw
Number of subjects: 15
Study 359266 — intervention group
Group type: COMPARATOR
Intervention: Cold water by sip
Number of subjects: 15
Study 359266 — intervention group
Group type: COMPARATOR
Intervention: Sham drinking procedure with straw
Number of subjects: 15
Study 30515978 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 124
Study 30515978 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 124
Study 28178150 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Laser Trabeculoplasty (SLT)
Number of subjects: 60
Study 28178150 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost (0.004%)
Number of subjects: 60
Study 25270327 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous walking speed with backward counting task
Number of subjects: 22
Study 25270327 — intervention group
Group type: EXPERIMENTAL
Intervention: Very slow walking speed with backward counting task
Number of subjects: 22
Study 25270327 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow walking speed with backward counting task
Number of subjects: 22
Study 25270327 — intervention group
Group type: COMPARATOR
Intervention: Sitting with cognitive performance assessment
Number of subjects: 22
Study 23629874 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A(H1N1)pdm09
Number of subjects: 566
Study 23629874 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza B
Number of subjects: 566
Study 23629874 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A(H1N1) and A(H3N2)
Number of subjects: 566
Study 23629874 — intervention group
Group type: EXPERIMENTAL
Intervention: Older index cases (age 11-14 years)
Number of subjects: 566
Study 23629874 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger infected household contacts (age ≤15 years)
Number of subjects: 566
Study 23629874 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater time spent in proximity to the index child
Number of subjects: 566
Study 21654265 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg/d
Number of subjects: 0
Study 21654265 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol 200 mg/d
Number of subjects: 0
Study 19494806 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs from DRD2, SLC6A3, and NR4A2 genes
Number of subjects: 828
Study 19494806 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC6A3 SNPs
Number of subjects: 828
Study 19494806 — intervention group
Group type: COMPARATOR
Intervention: Community cohort of N=175 multiplex ever-smoking pedigrees (N=423 ever smokers)
Number of subjects: 828
Study 16936143 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2155
Study 16936143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2155
Study 14574579 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (4 x (5 g Cr monohydrate + 2.5 g maltodextrin)/day)
Number of subjects: 12
Study 14574579 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation (4 x 7.5 g maltodextrin/day)
Number of subjects: 12
Study 14574579 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 12
Study 14574579 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 12
Study 11157325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (molar ratio 0.6:1)
Number of subjects: 19
Study 11157325 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2EDTA (molar ratios 0.3:1, 0.7:1, 1:1)
Number of subjects: 19
Study 11157325 — intervention group
Group type: COMPARATOR
Intervention: Control (no added enhancers)
Number of subjects: 19
Study 11157325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (molar ratio 1.6:1)
Number of subjects: 19
Study 11157325 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2EDTA (molar ratio 0.7:1)
Number of subjects: 19
Study 9776870 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training and dietary program in hypertensive group
Number of subjects: 56
Study 9776870 — intervention group
Group type: COMPARATOR
Intervention: Combined exercise training and dietary program in normotensive group
Number of subjects: 56
Study 8159193 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-week taper period
Number of subjects: 149
Study 8159193 — intervention group
Group type: COMPARATOR
Intervention: Nine-month taper period
Number of subjects: 149
Study 8159193 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental retardation presence
Number of subjects: 149
Study 8159193 — intervention group
Group type: EXPERIMENTAL
Intervention: Spikes in the electroencephalogram at tapering
Number of subjects: 149
Study 2659720 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (Pepti 2000)
Number of subjects: 43
Study 2659720 — intervention group
Group type: COMPARATOR
Intervention: Blended normal diet (placebo)
Number of subjects: 43
Study 768955 — intervention group
Group type: EXPERIMENTAL
Intervention: 780SE
Number of subjects: 0
Study 768955 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31486660 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral third-party perspective reappraisal
Number of subjects: 190
Study 31486660 — intervention group
Group type: EXPERIMENTAL
Intervention: Other party's perspective reappraisal
Number of subjects: 190
Study 31486660 — intervention group
Group type: COMPARATOR
Intervention: Control (reflecting on daily activities)
Number of subjects: 190
Study 28951468 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized management of NIV
Number of subjects: 47
Study 28951468 — intervention group
Group type: COMPARATOR
Intervention: Non-protocolized management of NIV (control group)
Number of subjects: 47
Study 28951468 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sample (both groups)
Number of subjects: 47
Study 26047993 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 2292
Study 26047993 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 2292
Study 21306457 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy (20 minutes daily from the day before surgery to the third postoperative day)
Number of subjects: 93
Study 21306457 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 93
Study 21306457 — intervention group
Group type: COMPARATOR
Intervention: Control group (no relaxation therapy)
Number of subjects: 93
Study 19967423 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa administered once a week (QW)
Number of subjects: 39
Study 19967423 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa administered every 2 weeks (Q2W)
Number of subjects: 39
Study 18929239 — intervention group
Group type: EXPERIMENTAL
Intervention: No anticoagulation therapy (no-heparin arm)
Number of subjects: 700
Study 18929239 — intervention group
Group type: COMPARATOR
Intervention: Standard anticoagulation regimen (control arm: 70 to 100 UI/kg unfractionated heparin)
Number of subjects: 700
Study 15876753 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional education
Number of subjects: 272
Study 15876753 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education
Number of subjects: 272
Study 15876753 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 272
Study 11806881 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral loratadine, once daily for three days
Number of subjects: 11
Study 11806881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10075338 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe group (60 mg Fe and 250 microg folate)
Number of subjects: 45
Study 10075338 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe+Zn group (60 mg Fe, 250 microg folate, and 15 mg Zn)
Number of subjects: 45
Study 10075338 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prenatal supplementation)
Number of subjects: 45
Study 8613581 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily toothbrushing programme with fluoride dentifrice
Number of subjects: 150
Study 8613581 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily toothbrushing programme with fluoride dentifrice plus weekly 0.2% fluoride rinse
Number of subjects: 150
Study 8613581 — intervention group
Group type: COMPARATOR
Intervention: Control group (De Villiers cohort)
Number of subjects: 150
Study 2124097 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment
Number of subjects: 28
Study 2124097 — intervention group
Group type: COMPARATOR
Intervention: Control group (uninfected Zaireans)
Number of subjects: 28
Study 6173896 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure with sensory and coping behavior information
Number of subjects: 50
Study 6173896 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory information
Number of subjects: 50
Study 6173896 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived control
Number of subjects: 50
Study 31558414 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically-predicted 50% increase of coffee consumption
Number of subjects: 588190
Study 31558414 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted median and MR-Egger methods
Number of subjects: 588190
Study 31558414 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee-related single-nucleotide polymorphisms based on association with blood levels of caffeine metabolites
Number of subjects: 588190
Study 28856093 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD‐EXP (reading intervention program: 4-hour sessions per day, 5 days a week for 10 weeks)
Number of subjects: 25
Study 28856093 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD‐EXP (reading intervention program)
Number of subjects: 25
Study 28856093 — intervention group
Group type: COMPARATOR
Intervention: ASD‐WLC (waitlist control group)
Number of subjects: 25
Study 26530648 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented Exeter stem
Number of subjects: 141
Study 26530648 — intervention group
Group type: COMPARATOR
Intervention: Uncemented Bimetric stem
Number of subjects: 141
Study 23557603 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher propensity for sexual arousability
Number of subjects: 701
Study 23557603 — intervention group
Group type: COMPARATOR
Intervention: Lower propensity for sexual arousability
Number of subjects: 701
Study 22067309 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor Desmopressin (DDAVP)
Number of subjects: 487
Study 22067309 — intervention group
Group type: COMPARATOR
Intervention: Control (nondopamine group)
Number of subjects: 487
Study 19142258 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium nitrate
Number of subjects: 75
Study 19142258 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer
Number of subjects: 75
Study 19142258 — intervention group
Group type: COMPARATOR
Intervention: Control (no substance)
Number of subjects: 75
Study 17533389 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant imatinib treatment
Number of subjects: 23
Study 17533389 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 23
Study 17198591 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward walking treadmill training (30-minute conventional training + 30-minute backward walking training, five times a week for three weeks)
Number of subjects: 26
Study 17198591 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (60 minutes, five times a week for three weeks)
Number of subjects: 26
Study 14659523 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture for 2 weeks
Number of subjects: 37
Study 14659523 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture (Streitberger needle) for 2 weeks
Number of subjects: 37
Study 10390201 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycosides administered twice daily
Number of subjects: 123
Study 10390201 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycosides administered once daily
Number of subjects: 123
Study 8894194 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 55
Study 8894194 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 55
Study 1672278 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic somatostatin infusion before, during, and after the procedure
Number of subjects: 16
Study 6711925 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane 0.5%
Number of subjects: 30
Study 6711925 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane 1.5%
Number of subjects: 30
Study 31483162 — intervention group
Group type: EXPERIMENTAL
Intervention: not willing/non-consent
Number of subjects: 615
Study 31483162 — intervention group
Group type: COMPARATOR
Intervention: refusal
Number of subjects: 615
Study 31483162 — intervention group
Group type: EXPERIMENTAL
Intervention: not willing/non-consent and refusal
Number of subjects: 615
Study 30845084 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite granules and bone marrow aspirate in collagen sponge
Number of subjects: 30
Study 30845084 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyapatite granules only
Number of subjects: 30
Study 27748055 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab (1 mg every 4 weeks)
Number of subjects: 423
Study 27748055 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab (3 mg every 4 weeks)
Number of subjects: 423
Study 27748055 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab (10 mg every 8 weeks)
Number of subjects: 423
Study 27748055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 27748055 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab (all doses)
Number of subjects: 423
Study 25798990 — intervention group
Group type: COMPARATOR
Intervention: Chef-enhanced meals
Number of subjects: 2638
Study 25798990 — intervention group
Group type: COMPARATOR
Intervention: Smart café intervention
Number of subjects: 2638
Study 25798990 — intervention group
Group type: COMPARATOR
Intervention: Chef plus smart café
Number of subjects: 2638
Study 25798990 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group
Number of subjects: 2638
Study 23688527 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 936
Study 23688527 — intervention group
Group type: COMPARATOR
Intervention: PPSV23
Number of subjects: 936
Study 23688527 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 (follow-on dose after 1 year)
Number of subjects: 936
Study 21715512 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-containing micronutrient powder (iron MNP)
Number of subjects: 268
Study 21715512 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder (PP)
Number of subjects: 268
Study 19458427 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) of the gluteus medius muscles during walking
Number of subjects: 21
Study 19458427 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES program with 15 minutes of simultaneous and continuous NMES of both gluteus medius muscles during walking, three sessions a day for a week
Number of subjects: 21
Study 19458427 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES program designed to detect additional changes in gait after adaptation to NMES
Number of subjects: 21
Study 19458427 — intervention group
Group type: COMPARATOR
Intervention: Control group of ten ambulant spastic diplegic children with CP
Number of subjects: 21
Study 19458427 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group with twenty normal children
Number of subjects: 21
Study 16675326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 40 microg/80 microg
Number of subjects: 26
Study 16675326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg/320 microg
Number of subjects: 26
Study 16675326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg
Number of subjects: 26
Study 15701185 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic excision of endometriomas with the stripping technique followed by serial transvaginal ultrasound examinations.
Number of subjects: 47